The new guidance, published in JACC, focuses on three classes of commonly used anticancer therapies.

After an official request from Edwards Lifesciences, CMS is rethinking its coverage policy for the use of TAVR to treat asymptomatic severe aortic stenosis. The agency is accepting public comments on this topic until Jan. 14. 

A fifth-generation TAVR valve from Edwards Lifesciences was associated with improved outcomes compared to the device's predecessors in a new real-world analysis out of Cedars Sinai.